Venous thromboembolism following major orthopedic surgery: What is the risk after discharge?

Orthopedics

Volumn 29, Issue 6, 2006, Pages 506-516

  Arcelus, Juan I ^a,e   Kudrna, James C ^b,c,d   Caprini, Joseph A ^b,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b NORTHWESTERN UNIVERSITY   (United States)

^c EVANSTON NORTHWESTERN HEALTHCARE   (United States)

^d ILLINOIS BONE AND JOINT INSTITUTE   (United States)

^e NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL PRACTICE; CLINICAL TRIAL; COMPRESSION THERAPY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LIVER TOXICITY; LOW DRUG DOSE; LUNG EMBOLISM; MORTALITY; ORTHOPEDIC SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; POSTOPERATIVE THROMBOSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; THROMBOSIS PREVENTION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 33745632369     PISSN: 01477447     EISSN: None     Source Type: Journal    
DOI: 10.3928/01477447-20060601-16     Document Type: Review

References (61)

1. Paiement GD, Mendelsohn C. The risk of venous thromboembolism in the orthopedic patient: epidemiological and physiological data. Orthopedics. 1997; 20(suppl):7-9.
2. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 126; 2004:338S-400S.
3. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol. 2001; 20:1-37.
4. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med. 1991; 115:591-595.
5. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med. 2000; 160:334-340.
6. Arcelus JI, Caprini JA, Motykie GD, Reyna JJ. Matching risk with treatment strategies in deep vein thrombosis management. Blood Coagul Fibrinolysis. 1999; 10(suppl 2):S37-S43.
7. Arcelus JI, Caprini JA, Reyna JJ. Finding the right fit: effective thrombosis risk stratification in orthopedic patients. Orthopedics. 2000; 23(6 suppl):s633-s638.
8. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003; 107(23 suppl 1):I9-I16.
9. Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol. 2001; 3 8(2 suppl 5):12-19.
10. Douketis JD, Eikelboom JW, Quinlan DJ, Willan AR, Crowther MA. Short-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of prospective studies investigating symptomatic outcomes. Arch Intern Med. 2002; 162:1465-1471.
11. Edelsberg J, Ollendorf D, Oster G. Venous thromboembolism following major orthopedic surgery: review of epidemiology and economics. Am J Health Syst Pharm. 2001; 58(suppl 2):S4-S13.
12. Gillespie W, Murray D, Gregg PJ, Warwick D. Risks and benefits of prophylaxis against venous thromboembolism in orthopaedic surgery. J Bone Joint Surg Br. 2000; 82:475-479.
13. Sigel B, Justin JR, Gibson RJ, et al. Risk assessment of pulmonary embolism by multivariate analysis. Arch Surg. 1979; 114:188-192.
14. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158:1525-1531.
15. Demers C, Marcoux S, Ginsberg JS, Laroche F, Cloutier R, Poulin J. Incidence of venographically proved deep vein thrombosis after knee arthroscopy. Arch Intern Med. 1998; 158:47-50.
16. Gallus AS. Applying risk assessment models in orthopaedic surgery: overview of our clinical experience. Blood Coagul Fibrinolysis. 1999; 10(suppl 2):S53-S61.
17. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest. 119 (1 suppl); 2001:132S-175S.
18. Freedman KB, Brookenthal KR, Fitzgerald RH Jr, Williams S, Lonner JH. A meta-analysis of thromboembolic prophylaxis following elective total hip arthroplasty. J Bone Joint Surg Am. 2000; 82:929-938.
19. Brookenthal KR, Freedman KB, Lotke PA, Fitzgerald RH, Lonner JH. A meta-analysis of thromboembolic prophylaxis in total knee arthroplasty. J Arthroplasty. 2001; 16:293-300.
20. Westrich GH, Haas SB, Mosca P, Peterson M. Meta-analysis of thromboembolic prophylaxis after total knee arthroplasty. J Bone Joint Surg Br. 2000; 82:795-800.
21. Zufferey P, Laporte S, Quenet S, et al. Optimal low-molecular-weight heparin regimen in major orthopaedic surgery. A meta-analysis of randomised trials. Thromb Haemost. 2003; 90:654-661.
22. Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res. 1995; 80:299-306.
23. Turpie AG, Bauer KA, Eriksson BI, Lassen MR. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162:1833-1840.
24. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost. 2003; 1:2490-2496.
25. Colwell CW Jr, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. J Thromb Haemost. 2003; 1:2119-2130.
26. Eriksson BI. Clinical experience of melagatran/ximelagatran in major orthopaedic surgery. Thromb Res. 2003; 109(suppl 1):S23-S29.
27. Is that it, then, for blockbuster drugs? Lancet. 2004; 364:1100.
28. FDA website: http://www.fda.gov/ohrms/dockets/ac/04/slides/ 2004-4069S1_03_He_files/frame.htm#slide0067.htm. Site accessed on December 14, 2004.
29. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162:1245-1248.
30. Kahn SR. The clinical diagnosis of deep vein thrombosis: integrating incidence, risk factors, and symptoms and signs. Arch Intern Med. 1998; 158:2315-2323.
31. McKenzie PJ, Wishart HY, Gray I, Smith G. Effects of anaesthetic technique on deep vein thrombosis. A comparison of subarachnoid and general anaesthesia. Br J Anaesth. 1985; 57:853-857.
32. Bucciarelli P, Rosendaal FR, Tripodi A, et al. Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. Arterioscler Throm Vasc Biol. 1999; 19:1026-1033.
33. White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med. 2000; 343:1758-1764.
34. Lassen MR, Borris LC, Backs S, Kaltoft-Sorensen M, Coff-Ganes H, Jeppensen E. Clinical limitations of risk assessment models. Blood Coagul Fibrinolysis. 1999; 10(suppl 2):S45-S51.
35. Scurr J, Baglin T, Burns H, et al. Risk of and prophylaxis for venous thromboembolism in hospital patients. Phlebology. 1998; 13:87-97.
36. Haas S. Prevention of venous thromboembolism: recommendations based on the International Consensus and the American College of Chest Physicians Sixth Consensus Conference on Antithrombotic Therapy. Clin Appl Thromb Hemost. 2001; 7:171-177.
37. Samama MM. Applying risk assessment models in general surgery: effective risk stratification. Blood Coagul Fibrinolysis. 1999; 10(suppl 2):S79-S84.
38. Haas S. Risikoabschätzung thromboembolischer Komplikationen bei chirurgischen Erkrankungen und Verletzungen. Akt Chir. 1996; 31:269-275.
39. Fitzgerald RH Jr. Post-discharge prevention of deep vein thrombosis following total Joint replacement. Orthopedics. 1996; 19(suppl):15-18.
40. Hull RD, Puneo GF. Extended prophylaxis against venous thromboembolism following total hip and knee replacement. Haemostasis. 1999; 29(suppl 4):23-25.
41. Hull RD, Pineo GF, Stein PD, et al. Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med. 2001; 161:1952-1960.
42. Hull RD, Pineo GF, Stein PD, et al. Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep vein thrombosis after elective hip arthroplasty: a systematic review. Ann Intern Med. 2001; 135:858-869.
43. Pineo GF, Hull RD. Prophylaxis of venous thromboembolism following orthopedic surgery: mechanical and pharmacological approaches and the need for extended prophylaxis. Thromb Haemost. 1999; 82:918-924.
44. Siragusa S, Beltrametti C, Barone M, Piovella F. Clinical course and incidence of post-thrombophlebitic syndrome after profound asymptomatic deep vein thrombos. Results of a transverse epidemiologic study [in Italian]. Minerva Cardioangiol. 1997; 45:57-66.
45. Dahl OE, Gudmundsen TE, Haukeland L. Late occurring clinical deep vein thrombosis in joint-operated patients. Acta Orthop Scand. 2000; 71:47-50.
46. Lie SA, Engesaeter LB, Havelin LI, Jessing HK, Vollset SE. Mortality after total hip replacement: 0-10-year follow-up of 39,543 patients in the Norwegian Arthroplasty Register. Acta Orthop Scand. 2000; 71:19-27.
47. Planes A, Vochelle N, Darmon JY, Agola M, Bellaud M, Huet Y. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomized comparison of enoxaparin versus placebo. Lancet. 1996; 348:224-228.
48. Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. Arch Intern Med. 2000; 160:2208-2215.
49. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost. 1997; 77:26-31.
50. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospective controlled randomized study. Arch Intern Med. 2002; 162:1966-1971.
51. Caprini JA, Arcelus JI, Motykie G, Kudrna JC, Mokhtee D, Rayna JJ. The influence of oral arrticoagulation therapy on deep vein thrombosis rates four weeks after total hip replacement. J Vasc Surg. 1999; 30:813-820.
52. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet. 2001; 358:9-15.
53. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty- the Danish Prolonged Prophylaxis (DaPP) Study Thromb Res. 1998; 89:281-287.
54. Bergqvist D, Benoni G, Björgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med. 1996; 335:696-700.
55. Samama CM, Way M, Barré J, et al. Extended venous thromboembolism prophylaxis after total hip replacement: a comparison of low-molecular-weight heparin with oral anticoagulant. Arch Intern Med. 2002; 162:2191-2196.
56. Eriksson BI, Lassen MR. Consistency of efficacy of extended thromboprophylaxis with fondaparinux (Arixtra) in prevention of venous thromboembolism (VTE) after hip fracture surgery according to different composite efficacy endpoints: the PENTHIFRA-PLUS study. J Thromb Haemost. 2003; suppl 1: 2064.
57. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest. 2003; 124 (6 suppl):386S-392S.
58. Friedman RJ, Dunsworth GA. Cost analysis of extended prophylaxis with enoxaparin after hip arthroplasty. Clin Orthop. 2000; 370:171-182.
59. Marchetti M, Liberato NL, Ruperto N, Barosi G. Long-term cost-effectiveness of low molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement. Haematologica. 1999; 84:730-737.
60. Davies LM, Richardson GA, Cohen AT. Economic evaluation of enoxaparin as post-discharge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery. Value Health. 2000; 3:397-406.
61. Detournay B, Planes A, Vochelle N, Fagnani F. Cost-effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement. Pharmacoeconomics. 1998; 13(1 pt 1):81-89.